Lagomics
Lagomics is an early-stage biotech pairing generative AI protein design with a cell-free, DNA-barcoded multiplex validation platform that tests thousands of AI-designed protein interactions in a single run.
About
Lagomics is an early-stage biotech pairing generative AI protein design with a cell-free, DNA-barcoded multiplex validation platform that tests thousands of AI-designed protein interactions in a single run. It runs women's-health therapeutic programs and supplies protein actives to cosmetics formulators; it is based at MBC BioLabs and supported by Activate, MIT Engine Blueprint and NVIDIA.
Capital graph
Founders / team· 2
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Lagomics
Lagomics is an early-stage biotech pairing generative AI protein design with a cell-free, DNA-barcoded multiplex validation platform that tests thousands of AI-designed protein interactions in a single run. It runs women's-health therapeutic programs and supplies protein actives to cosmetics formulators; it is based at MBC BioLabs and supported by Activate, MIT Engine Blueprint and NVIDIA.
—
United States
BusinessLatest roundTotal raisedDate- Diffuse Bio
Diffuse Bio is a generative-AI protein design company founded in 2022 and backed by Y Combinator (W23). It pairs diffusion-model design software (DiffuseSandbox) with wet-lab screening (RamaX) for therapeutic proteins, vaccines and enzymes, and is expanding into generating verified biological reward signals at scale for AI models.
$500K
$500K - Iambic Therapeutics
Uses AI to predict protein-ligand structures and generate molecular designs to discover new drugs
IPO · $462M · 2026-09
$462M - Odyssey Therapeutics
Small-molecule and protein therapeutics developed with AI and machine learning
Series C · $101M · 2023-12
$101M
China
BusinessLatest roundTotal raisedDate- Matwings Technology
Protein design model MatwingsVenus with an automated lab platform, doing enzyme mining and directed evolution for universities and pharma companies
Series A · 2026-07
— - Levinthal Biotech
AI protein design services, with the proprietary all-atom protein design platform Pallatom
Series A · $14M · 2025-12
$14M - 途深智合
AI protein design platform; conversational protein design platforms ProteinNova/ProteinEngine covering site-directed mutagenesis, enzyme engineering, de novo design, antibody structure and more
Angel · $1M · 2025-09
$1M
Europe
BusinessLatest roundTotal raisedDate- Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds its own therapeutic pipeline and conducts joint R&D with large pharmaceutical companies
Series B · $2.7B · 2026-05
$2.7B - Alchemab Therapeutics
AI-based discovery and development of therapeutic antibodies from "naturally resistant" populations
Series A · $32M · 2025-09
$32M - Adaptyv Biosystems
AI protein design
Series A · 2026-09
—
Other / unspecified
BusinessLatest roundTotal raisedDate- Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M - Halmos Labs
AI-driven automated R&D systems for biotech and pharma that simulate experimental outcomes before wet-lab work and recommend the experiments that most reduce uncertainty
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in United States
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.